Laccure has developed a new innovative product for one-time treatment of bacterial vaginosis to meet the needs of women for efficacy, safety and user-friendliness. Laccure’s novel, non-prescription vaginal tablet has been tested in randomized, controlled clinical multicenter studies including 126 women. The results show a cure rate of 80% following a single administration of one (1) vaginal tablet. Along with a good safety profile and by fully meeting women’s need for user-friendly comfort, this represents a major improvement in the treatment of bacterial vaginosis.

Laccure was founded in 2007. In 2017, Laccure AB and Combe Inc. signed an agreement awarding Combe the exclusive license to market and sell Laccure’s female health product globally. Combe terminated the license arrangement in the beginning of 2019 due to change in the company’s priorities and strategy for its development projects and the product was handed back to Laccure.

Since taking back the product in the spring of 2019, Laccure has developed a completely new cost-effective production method that also considerably simplifies large-scale production. During the second quarter of 2020, the production method was evaluated with regard to the stability of the product and since the initial analyses gave good results, the evaluation of stability continued in the fall of 2020. The goal is to complete production development and following a positive outcome, to initiate new discussions with potential partners who can take the product further toward registration and commercialization.

Laccure is an affiliated project and AQILION AB owns a 25.9% stake (December 31, 2020) in Laccure AB.